TICKERNERD
Menu
TENXTENXHealthcare · Biotechnology

TENX Stock Forecast: Tenax Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.75
−1.69% on the day

The 10 Wall Street analysts covering Tenax Therapeutics, Inc. hold a median 12-month price target of $5 — +185.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$65.5M
Ticker Nerd rank
31 / 100
Median analyst target
$5.00
Analysts covering
10
Total return, dividends reinvested
1W
−2.8%
1M
−88.9%
YTD
−85.6%
1Y
−71.0%
From 52W high
−90.4%
From 52W low
+27.3%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TENX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tenax Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
80
Revisions
64
Volatility
60
Momentum
53
Quality
52
Accruals
49
Issuance
23
Growth
10
Value
6

Size (80): Smaller than most of the companies we track.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TENX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TENX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26TENXHigh $36.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
7 Buy3 Hold0 Sell
Low $4.00Median $5.00High $36.00

The green dot is the last close — the median target sits +185.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
11 Aug 2026Canaccord GenuityMaintainsBuy$35 → $4.00
11 Aug 2026Chardan CapitalDowngradeNeutral$27 → $5.00
11 Aug 2026Evercore ISI GroupDowngradeIn-Line$39 → $5.00
11 Aug 2026GuggenheimMaintainsBuy$40 → $4.00
10 Aug 2026William BlairDowngradeMarket Perform—
31 July 2026Chardan CapitalMaintainsBuy—
31 July 2026Chardan CapitalMaintainsBuy$27
29 July 2026Cantor FitzgeraldReiteratesOverweight—
29 July 2026Cantor FitzgeraldReiteratesOverweight$35
28 July 2026Canaccord GenuityInitiatesBuy$35
28 July 2026Canaccord GenuityInitiatesBuy—
22 July 2026Evercore ISI GroupInitiatesOutperform$39
22 July 2026Evercore ISI GroupInitiatesOutperform—
2 July 2026Chardan CapitalMaintainsBuy$27
2 July 2026Chardan CapitalMaintainsBuy—
24 June 2026Cantor FitzgeraldReiteratesOverweight—
22 June 2026Chardan CapitalInitiatesBuy—
22 June 2026GuggenheimMaintainsBuy—
12 June 2026Piper SandlerMaintainsOverweight—
17 Mar 2026Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TENX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TENX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Tenax Therapeutics, Inc. (TENX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.4×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 80% of US stocks

EV / EBITDA
0.3×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.8%

Higher than 19% of US stocks

Return on assets
−37.7%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TENX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TENXTenax Therapeutics, Inc.$65.5M
31
HYFTMindWalk Holdings Corp.$65.8M
57
IMAImageneBio, Inc.$65.1M
28
EXOZeXoZymes, Inc.$66.4M
11
BOLDBoundless Bio, Inc.$67.2M
74
CRDFCardiff Oncology, Inc.$67.8M
42
BSEMBioStem Technologies, Inc.$63.1M
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tenax Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TENX news & analysis

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

PRNewsWire · 19 Aug 2026negative

Tenax Therapeutics shares fell approximately 84% to 85% after the company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered losses.

Why it matters — The failed Phase 3 trial results caused a sharp decline in Tenax's share price and triggered a securities investigation, making this a significant development for TENX investors.

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Business Wire · 16 Aug 2026negative

SBS Law announced an opportunity for Tenax Therapeutics, Inc. (TENX) investors to join a fraud investigation into the company. The notice was issued via Business Wire, inviting affected investors to participate.

Why it matters — A fraud investigation being pursued by a law firm signals potential legal and reputational concerns for Tenax Therapeutics that shareholders may wish to monitor.

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

Business Wire · 14 Aug 2026negative

Tenax Therapeutics disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both primary and key secondary endpoints, causing its share price to drop approximately 84% to 85%. Levi & Korsinsky has notified investors of an investigation into the company.

Why it matters — The failed trial and resulting investigation are significant for TENX watchers because the company's lead drug candidate missed its endpoints, erasing most of the company's shareholder value.

Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

PRNewsWire · 12 Aug 2026negative

Levi & Korsinsky has notified investors of a pending investigation into Tenax Therapeutics after the company announced its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. The disclosure reportedly erased approximately 84% to 85% of shareholder value, and those losses may carry legal rights.

Why it matters — TENX watchers would care because the missed Phase 3 endpoints triggered a massive shareholder value decline and a potential legal investigation into the company.

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

MarketBeat · 11 Aug 2026neutral

Tenax Therapeutics reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.

Why it matters — A TENX watcher would care because the trial's missed primary endpoint is a significant clinical setback, though the reported subgroup, biomarker and hemodynamic data may shape the future direction of the levosimendan program.

FAQ

Frequently asked questions about TENX stock

What is the TENX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Tenax Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TENX stock a buy right now?

Of the 10 analysts covering Tenax Therapeutics, Inc., 7 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenax Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TENX?

As at 22 Aug 2026, Tenax Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).

Will TENX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +185.7% from the last close, and Ticker Nerd's factor model ranks Tenax Therapeutics, Inc. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TENX stock forecast for 2030?

No analyst covering Tenax Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TENX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $36 over the next 12 months.

How has TENX stock performed over the past year?

Tenax Therapeutics, Inc. returned -71.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tenax Therapeutics, Inc. do?

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases with significant unmet medical need.

What is the latest news on TENX?

The most recent item we track (PRNewsWire, 19 Aug 2026): "Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky". Tenax Therapeutics shares fell approximately 84% to 85% after the company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered losses.

Company

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases with significant unmet medical need. The company’s current pipeline centers on cardiopulmonary programs, including TNX-103, an oral formulation of levosimendan being studied for pulmonary hypertension associated with heart failure with preserved ejection fraction, and TNX-201, a modified-release imatinib program for pulmonary arterial hypertension. Tenax Therapeutics also works on related formulations and delivery approaches designed to improve treatment options in serious heart and lung conditions. Based in Chapel Hill, North Carolina, Tenax Therapeutics plays a role in the biotechnology market as a development-stage company advancing targeted medicines for complex cardiopulmonary disorders.

CEO Mr. Christopher T. Giordano · 14 employees · United States · https://www.tenaxthera.com